Acute Lymphocytic Leukemia (ALL) is also known as acute lymphoblastic leukemia, is a cancer of white blood cell or bone marrow, which occurs due to overproduction and accumulation of cancerous white blood cell, known as lymphoblasts. ALL is an acute form of leukemia which majorly affects the lymphoid system, blood and bone marrow. This type of leukemia is more dominant in infants, however, it can be also diagnosed in adults. The common symptoms of ALL a patient exhibits are weakness, tiredness, dizziness, fever, shortness of breath, frequent infections, bruising, and bleeding. Globally, the growing awareness about ALL among the consumers has primarily driven the demand for drugs and treatment of acute lymphocytic leukemia. In 2015, the size of global acute lymphocytic leukemia market was valued at USD XX million. The value of global acute lymphocytic leukemia market is projected to grow with a CAGR between 4.0% – 5.0% during the forecast period of 2016-2022 and reach USD XX million by 2022.
The growth in acute lymphocytic leukemia market is primarily driven by unmet healthcare needs coupled with innovative therapies. Moreover, provision for orphan drugs is majorly contributing to the growth of this market. However, High cost of production, adverse effect of drugs and entry of generics are considered to be the major restraining factors that are likely to hinder the growth of this market over the forecast period. Yet, the global acute lymphocytic leukemia market is expected to present several opportunities to the leading players in the market over the forecast period, due to growing unmet healthcare needs and minimal competition.
The report segments the acute lymphocytic leukemia market by therapeutics, by rout of administration, by types of molecule and by region. Market segmentation based on therapeutics includes existing drugs and pipeline drugs. Existing drugs are further sub segmented into CALGB 8811 regimen, hyper CVD regimen, linker regimen, nucleoside regimen and oncasper; Pipeline drugs are further sub segmented into margibo, graspa, inotuzumab ozogamicin. Based on route of administration, market segmented into oral and parental. Types of molecules segment comprise biologics and small molecules.
Geographic Coverage and Analysis
The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the largest acute lymphocytic leukemia market globally, with a market share of more than XX%. The market growth in North America is majorly driven by the large number of patients detected with ALL in this region, especially in the U.S. Europe is the second largest market for ALL; growth in this region is attributed to special provision for orphan drugs by European Medicine Agency due to which vendors enjoy ten years of market exclusivity for their products. However, Asia pacific is anticipated to grow at fastest CAGR of 5.X% over the forecast period. This is due to rise in public awareness about the disease that will propel the market growth.
The companies covered in the report include
Talon Therapeutic, Inc.,
Sigma-Tau Pharmaceuticals, Inc., and